Idexx Laboratories (IDXX)
NASDAQ:IDXX
Want to see IDXX full AI Analyst Report?
IDXX Stock Chart & Stats
$589.25
$7.33(1.72%)
At close: 4:00 PM EST
$589.25
$7.33(1.72%)
Day’s Range― - ―
52-Week Range$496.61 - $769.98
Previous CloseN/A
Volume277.29K
Average Volume (3M)487.23K
Market Cap
$41.71B
Enterprise Value$42.59B
Total Cash (Recent Filing)$200.53M
Total Debt (Recent Filing)$1.08B
Price to Earnings (P/E)40.4
Beta0.84
Next Earnings
Aug 04, 2026EPS Estimate
3.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.67
Shares Outstanding78,882,996
10 Day Avg. Volume469,929
30 Day Avg. Volume487,228
Financial Highlights & Ratios
PEG Ratio2.30
Price to Book (P/B)33.75
Price to Sales (P/S)12.59
P/FCF Ratio51.44
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.58
Enterprise Value/Gross Profit15.44
Enterprise Value/Ebitda28.01
Forecast
1Y Price Target
$693.17Price Target Upside17.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)14.64
Revenue Forecast (FY)$4.71B
Bulls Say, Bears Say
Bulls Say
Earnings And GuidanceReported quarterly results beat sales and profit expectations and management issued guidance that points to continued organic revenue growth and margin expansion, reinforcing a constructive earnings outlook.
Product InnovationA robust pipeline of diagnostic and cancer-related products plus growing placements of instruments and software are driving recurring consumables and service revenue, supporting longer-term growth.
Supply Chain EfficiencyProgress in global logistics optimization, such as shifting shipments from air to ground, has reduced transportation costs and helped offset fuel-related price pressures on margins.
Bears Say
Demand TrendsTotal veterinary office visits remain pressured and a shift in the pet mix toward animals that visit clinics less often is reducing overall visit volumes, creating a demand headwind for core consumables and services.
Margin PressureRising oil-related input costs for plastics and resins, together with tariffs and reinvestment, are expected to weigh on operating margins and could soften reported profitability.
Valuation RiskThe stock trades at a premium valuation that leaves limited room for multiple expansion, making shares sensitive to macro uncertainty and dampening upside from product milestones.
Idexx Laboratories News
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest stock price was $496.61 and its highest was $769.98 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $41.71B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Aug 04, 2026 which is in 79 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on May 05, 2026. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 3.95.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 78,882,996 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $3.47 in its last earnings report, beating expectations of $3.41. Following the earnings report the stock price went down -0.028%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Currently, no hedge funds are holding shares in IDXX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Idexx Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$693.17 (17.64% Upside)
$693.17 (17.64% Upside)
Blogger Sentiment
Bullish
IDXX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 242.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $29.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.19%
12-Months-Change
Fundamentals
Return on Equity
70.87%
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
IDXX Company Deck
IDXX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line growth, robust recurring revenue and instrument placement momentum, margin expansion, healthy EPS and cash generation, and continued adoption of new diagnostic innovations (inVue Dx, Cancer DX) and software solutions. These positives substantially outweigh the headwinds disclosed: modest declines in clinical visits (especially wellness), flat rapid assay revenues due to platform migration, some supply-chain impacts in Water, and a few discrete expense items (equity loss, prior litigation). Management raised full-year guidance and reaffirmed growth drivers while acknowledging macro and FX sensitivities. Overall, the tone is confident and constructive with execution-focused follow-through on innovation rollouts and international expansion.View all IDXX earnings summariesIDXX Revenue Breakdown
91.86% CAG
4.67% Water
3.06% LPD
0.41% Other
IDXX Stock 12 Month Forecast
Average Price Target
$693.17
▲(17.64% Upside)
Technical Analysis
Ownership Overview
0.23% Insiders
27.94% Mutual Funds
23.52% Other Institutional Investors
16.66% Public Companies and
Individual Investors